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Abstract: Aspartame (ASP) is one of the most widely used nonnutritive sweeteners. This study investigates the 
chronic effects of ASP on hematological and biochemical parameters, and its effects on the oxidative/antioxida-
tive status in the red blood cells of Wistar albino rats. Rats were provided with ASP (40 mg/kg/daily for six weeks) 
in drinking water. Increased food and fluid intake was observed in the ASP-treated rats. Total body mass was 
significantly decreased in the ASP-treated rats. Treatment with ASP caused an increase in the concentrations of 
glucose, cholesterol, LDL-cholesterol, and in the activities of alanine aminotransferase (ALT), aspartate amino-
transferase (AST) and lactate dehydrogenase (LDH), as well as a decrease in the levels of HDL-cholesterol in the 
serum. A significant decline in the number of white blood cells (WBC) was observed after ASP uptake. Based 
on the results we conclude that ASP induces oxidative stress, observed as an alteration of the glutathione redox 
status, which leads to increased concentrations of nitric oxide (NO) and lipid peroxides (LPO) in the red blood 
cells. Changes in biochemical parameters, lipid metabolism, as well as changes in the levels of oxidative stress 
markers and the appearance of signs of liver damage indicate that chronic use of ASP can lead to the develop-
ment of hyperglycemia, hypercholesterolemia and associated diseases.
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INTRODUCTION
In the last couple of decades, growing concern 
about health and life quality has encouraged 
people to exercise, eat healthy food and decrease 
the consumption of food rich in sugar, salt and 
fat (Butchko et al., 2002; Appleton and Blundell, 
2007). Subsequently, the use of products such as 
artificial sweeteners has increased. Nonnutritive 
sweetener (NNS) consumption has been histori-
cally associated with the increasing prevalence of 
obesity (Yang, 2010). 
NNS can replace the sugar in food and 
beverages, resulting in reduced or non-calorie 
products (Butchko et al., 2002). Aspartame (L-
aspartyl-L-phenylalanine methyl ester, ASP) 
is one of the most widely used nonnutritive 
sweeteners, widespread in over 90 countries in 
about 6 000 products (Magnuson et al., 2007). 
It is about 200 times sweeter than sucrose. Af-
ter oral administration, ASP is metabolized into 
three components, two amino acids (50% phe-
nylalanine - Phe and 40% aspartic acid - aspar-
tate, Asp) and 10% methanol (MeOH). Aspar-
tame produces effects through its metabolites 
(Humphries et al., 2008). 
Phenylalanine and aspartic acid are both 
amino acids found in natural proteins, and under 
normal circumstances are beneficial, if not essen-
tial, for health (Magnuson et al., 2007). Phenyl-
alanine is a precursor in the synthesis of tyrosine 
(Walton, 1988), DOPA, dopamine, norepineph-
rine, epinephrine, phenylethylamine (Magnuson 
et al., 2007; Humphries et al., 2008). Aspartate is 
an excitatory neurotransmitter and is normally 
found in high levels in the brain where it stimu-
lates N-Methyl-D-aspartate (NMDA) receptors 
(Chen et al., 2005). 
Small amounts of ASP can significantly in-
crease methanol concentration in the blood-
stream. MeOH has a relatively low toxicity, but 
its metabolites are very toxic. It is increasingly 
recognized as a substance that damages the liver 
cells, where it is oxidized to formaldehyde and 
then to formate (Parthasarathy et al., 2006). 
These processes are accompanied by an elevation 
in NADH level and the formation of superoxide 
anion, which may be involved in lipid peroxida-
tion (Castro et al., 2002). Methanol intoxication 
is associated with mitochondrial damage and 
increased microsomal proliferation, which re-
sults in the overproduction of oxygen radicals 
(Humphries et al., 2008). These factors, together 
with the excess of formaldehyde formed during 
acute methanol intoxication, cause a significant 
increase in lipid peroxidation (Parthasarathy et 
al., 2006; Humphries et al., 2008). 
After ASP consumption, the concentration of 
its metabolites increases in the blood (Humphries 
et al., 2008). After tissue damage, some of the 
enzymes find their way into the serum leaking 
through membranes with altered permeability. 
Activity measurements of serum enzymes (as-
partate aminotransferase (AST), alanine amino-
transferase (ALT), lactate dehydrogenase (LDH) 
and γ-glutamyl transpeptidase (γGT)) are a valu-
able tool in clinical diagnosis. The measurement 
of these enzymes’ activities in tissues and body 
fluids can be used to estimate the degree of toxic-
ity of a chemical compound on an organ/tissues 
(Vijan, 2010; Abhilash et al., 2011).
Clinical studies have shown that the admin-
istration of ASP could be responsible for neu-
rological and behavioral disturbances in sensi-
tive individuals (Walton, 1988; Iyyaswamy and 
Rathinasamy, 2012). In addition, the chronic 
ASPARTAMe effeCT ON BLOOD PARAMeTeRS 537
use of ASP might contribute to hypersensitivity 
reactions and atherosclerosis (Walton, 1988; 
Butchko et al., 2002; Jang et al., 2011). The ef-
fects of long-term consumption of ASP prod-
ucts have not yet been discussed.
The aim of this study was to investigate the 
chronic effects of ASP (40 mg/kg b.w.) on hema-
tological parameters, glucose and lipid profiles, 
activities of hepatic marker enzymes, and its 
effects on oxidative stress parameters and glu-
tathione redox status in red blood cells of male 
Wistar rats. 
Table 1. effect of aspartame (ASP) on body weight, calories, food 
and water intake.
Parameters
Experimental groups
Control ASP
Initial body weight (g) 204 ± 9.2 208 ± 16.8
final body weight (g) 486 ± 15.7 476 ± 26.4
Gain of body weight (g) 282 ± 6.5* 268 ± 8.4
food intake (g/rat/day) 26.2 ± 1.2 29.2 ± 1.3
Caloric intake (kcal/rat/day) 79.1 ± 3.6 88.2 ± 3.8*
Water intake (mL/rat/day) 46.0 ± 1.7 47.8 ± 1.8
Values are expressed as means ± S.e.M. (n = 5 animals). *p<0.05 
when compared with the control group.
Table 2. effect of aspartame (ASP) on haematological parameters.
Parameters
Experimental groups
Control ASP
RBC (x 1012 /L) 5.25 ± 0.31 5.47 ± 0.12
Hb (g/L) 116.5 ± 4.15 98.3 ± 2.31
Hct (%) 38.57 ± 0.76 35.74 ± 0.27
WBC (x 109 /L) 4.58 ± 0.26 3.84 ± 0.17*
PLT (x 109 /L) 574.8 ± 31.5 667.2 ± 29.7
RBC: red blood cell; Hb: haemoglobin; Hct: haematocrit values; 
WBC: white blood cell; PLT: platelets. Values are expressed as 
means ± SeM, (n = 5 animals). *p<0.05 when compared with the 
control group.
MATERIALS AND METHODS
Chemicals
Chemicals for this study were obtained from 
Sigma Chemical Co. (St. Louis, MO, USA) and 
Merck (Darmstadt, Germany). All reagents and 
chemicals were of analytical grade or higher 
purity.
Animals and treatment
Male Wistar albino rats (2 months old, weigh-
ing 190-220 g) were used. The animals were kept 
under standard laboratory conditions (12 h light/
dark intervals; 21 ± 2°C). All rats were housed 
in individual cages (44 x 34 x 16 cm). Standard 
food and water were available ad libitum for all 
groups. The University Committee of the ethics 
of Animal experimentation approved all animal 
experiments. The european food Safety Author-
ity (efSA) established 40 mg/kg as an Accept-
able Daily Intake (ADI) for ASP. The animals 
were divided into two groups (n = 5 per group) 
and treated as follows: Group 1 (control group), 
included rats that were provided with normal 
drinking water; Group 2 (experimental group) 
included rats that were provided with ASP (40 
mg/kg b.w., p.o.) via drinking water for 6 weeks.
Measurements of food and fluid intake  
and mass gain
The control of food and fluid intake was con-
ducted daily by subtraction of the quantity re-
maining (g, ml) from the quantity supplied (g, 
ml). The daily consumption of both groups was 
registered and summarized weekly. Cages were 
carefully monitored for any evidence of food 
spillage and crumbs were considered for the con-
trol of food intake. The fluid bottles were also 
538 Prokić et al.
checked for any sign of leaking or clogging. The 
rats were weighed weekly at the same time in the 
morning. An electronic precision balance (BJ 
610C, Precisa) was used for all these measure-
ments and data collectors were blinded to group 
assignments.
Blood sampling
Animals were anesthetized with ether and killed 
by decapitation. Blood samples were collected be-
tween 8 and 10 a.m. to avoid circadian rhythm-
induced changes. The blood samples were col-
lected in tubes using K-eDTA as anticoagulant 
for hematological analysis, and in tubes without 
anticoagulants for the other analysis. Hematolog-
ical and biochemical parameters were performed 
on the day of sacrifice. 
Hematological methods
eDTA-added whole blood samples were used 
for hematological examination. Hematological 
parameters such as the number of red blood cells 
(RBC), white blood cells (WBC), platelets (PLT), 
hemoglobin (Hb) concentration and hematocrit 
(Hct) values, were determined in whole blood 
by standard methods on an automated hematol-
ogy analyzer (Horiba Medical ABX Micros 60, 
Japan). 
Biochemical methods
Blood samples in non-anticoagulant tubes 
were centrifuged at 5 000 rpm for 15 min and 
the serum was used. Measurement of biochem-
ical parameters (serum total protein (TP), al-
bumin (Alb), glucose, total cholesterol (TC), 
high density lipoprotein (HDL)-cholesterol, 
low density lipoprotein (LDL)-cholesterol, 
and activities of AST, ALT and LDH) were per-
formed on an autoanalyzer (C 8000 Architect, 
Germany) using diagnostic colorimetric kits 
(Abbott laboratories).
Oxidative stress parameters
To measure oxidative stress parameters, blood 
samples were centrifuged and the plasma was 
removed. erythrocytes were washed three times 
with an equal volume of cold saline (0.9%, v/v), 
and 1 ml of washed erythrocytes was lysed on 
ice in 3 ml of dH2O (1:3, v/v) for 30 min. Ni-
tric oxide (NO) levels were measured as total 
nitrite and nitrate levels with the use of Griess 
reagent according to the method of Green et 
al. (1982). Concentrations were expressed as 
μmol/L erythrocytes. 
The lipid peroxide (LPO) level was deter-
mined based on the reaction of products of lipid 
peroxidation (MDA − malondialdehydes) with 
TBA (thiobarbituric acid reactive substances − 
TBARS analysis) using method of Ohkawa et 
al. (1979). These results were expressed in μmol 
MDA/L erythrocytes using a molar extinction 
coefficient for MDA of 1.56 × 105 M−1·cm−1.
Determination of reduced  
and oxidized glutathione
Quantification of reduced glutathione (GSH) 
was accomplished using the method of Beutler 
(1975a) based on the oxidation of GSH with 
DTNB (5.5-dithiobis-2-nitrobenzoic acid). GSH 
concentrations were expressed as mmol/L eryth-
rocytes. The level of oxidized glutathione (GSSG) 
was determined after enzymatic reaction with 
glutathione reductase and inhibition of GSH 
oxidation by NeM (N-ethylmaleimide) (Beu-
tler, 1975b). The concentrations were expressed 
as μmol/L erythrocytes. The glutathione redox 
index (GSH RI) was calculated and expressed in 
arbitrary units.
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Statistical analysis
All data were statistically evaluated with SPSS/13 
software. The results were expressed as mean ± 
S.e.M. and analyzed by factorial analysis of vari-
ance (ANOVA) using a post hoc Bonferroni/
Dunnett’s multiple analysis, or by nonparametric 
Kruskal-Wallis test, where p<0.05 was considered 
statistically significant.
RESULTS
Effect of ASP on body weight, weight gain, 
calories, food and water intake
Table 1 summarizes the weight gain data for the 
control rats and ASP-treated rats, along with 
their daily ingestion of water, food and calories. 
Average daily food and water consumption as 
well as caloric intake during the experiment show 
increased intake in rats treated with ASP. The in-
crease was statistically significant only in caloric 
intake. fig. 1 presents the average weekly food 
intake during the experiment. The ASP-treated 
group increased food intake during the third, 
fourth, fifth and sixth weeks in comparison to the 
control group. Intake was statistically increased 
during the third and fourth week (p<0.05). The 
results of weekly average water intake show a 
slightly increased intake in ASP-treated group 
during the first, third and fourth weeks com-
pared to control group (fig. 2). Weekly changes 
in body weight and weight gain are presented in 
figs. 3 and 4. Increase of total body weight (fig. 
3) was observed in the group treated with ASP 
during the first and fourth week, while the value 
of weight gain (fig. 4) was detected to be signifi-
cantly higher (p<0.05) in the ASP-treated group 
only in the fourth week compared to the control 
rats. During the first, second and sixth weeks 
of the experiment, a significantly lower weight 
gain was reported (p<0.05) in ASP-treated group 
(fig. 4). Total body weight gain was significantly 
higher (p<0.05) in the control group compared 
to the ASP-treated group (Table 1).
Effect of ASP on hematological parameters
The results of hematological parameters of con-
trol and rats treated with ASP are presented in 
Table 2. As can be observed, there were no sig-
nificant changes in the number of RBC and PLT, 
Hb concentration and Hct values between the 
treated and control groups. However, the results 
indicated a significant decline (p<0.05) in white 
blood cell number after ASP treatment.
Effect of ASP on biochemical parameters
The effects of ASP on the biochemical param-
eters in serum are shown in Table 3. The present-
ed results show a significant increase (p<0.05) in 
serum glucose, TC and LDL-cholesterol, while 
the level of HDL-cholesterol was decreased in the 
ASP-treated group compared to the control. No 
significant changes in serum total proteins and 
albumins were found in the rats treated with ASP 
compared to the control group. 
As expected, ASP administration significantly 
increased (p<0.05) the activities of ALT, AST and 
LDH in the serum compared to the control group 
(Table 3).
Effect of ASP on oxidative stress parameters 
and glutathione redox status
The effects of ASP on oxidative stress parameters 
in the erythrocytes of the rats are shown in Table 
4. The obtained results indicated that the con-
centrations of NO and LPO in erythrocytes sig-
nificantly increased (p<0.05) in the group treated 
with ASP compared to the control group. 
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The data presented in Table 4 show signifi-
cant changes in the glutathione redox status 
(GSH, GSSG, GSH RI) after the ASP treatment. 
The concentration of GSH and glutathione redox 
index significantly decreased (p<0.05), while the 
concentration of GSSG significantly increased 
(p<0.05) in the group treated with ASP in com-
parison to the control. 
DISCUSSION
ASP use has been approved by the fDA and 
the european Commission Scientific Commit-
tee on food. The acceptable daily intake level 
of ASP established by the fDA and european 
food Safety Authority is 50 and 40 mg/kg/
day. People on diet and patients with diabetes, 
Fig. 1. Weekly change in food intake in control and rats treated 
with aspartame (ASP, 40 mg/kg b.w.). Values are expressed as 
means ± S.e.M. (n = 5 animals). *p<0.05 when compared with 
the control group.
Fig. 2. Weekly change in water intake of control and rats treated 
with aspartame (ASP, 40 mg/kg b.w.). Values are expressed as 
means ± S.e.M. (n = 5 animals). *p<0.05 when compared with 
the control group.
Fig. 3. Weekly change in body weight of control and rats treated 
with aspartame during experiment (ASP, 40 mg/kg b.w.). Values 
are expressed as means ± S.e.M. (n = 5 animals). *p<0.05 when 
compared with the control group.
Figure 4. Weekly weight gain in control and rats treated with 
aspartame (ASP, 40 mg/kg b.w.). Values are expressed as means ± 
S.e.M. (n = 5 animals). *p<0.05 when compared with the control 
group.
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including children, frequently use these prod-
ucts. In our study, we report that ASP increased 
appetite in rats. Appetite is a highly regulated 
phenomenon with hunger and satiety as crucial 
factors in controlling food intake. Both food in-
take and energy expenditure disturbances lead 
to obesity, a pandemic syndrome frequently as-
sociated with the most prevalent and morbid 
pathologies in developed countries, including 
heart disease, atherosclerosis, diabetes and can-
cer (Das, 2010). Sweetness in the absence of en-
ergy has been hypothesized to have effects on 
appetite because of a natural sweetness-energy 
association. Sweetness is naturally found in asso-
ciation with energy. Because of this association, 
it has been suggested that sweetness could cue 
the arrival of the associated energy and its phys-
iological and psychological effects on appetite 
(Appleton and Blundell, 2007). The absence of 
the associated energy, as occurs in an artificially 
sweetened beverage, has been suggested to result 
in a need for energy, leading to the stimulation 
of appetite (Swithers and Davidson, 2008). ASP 
increases appetite through its metabolites by dif-
ferent mechanisms. An increased phenylalanine 
concentration releases cholecystokinin (Gibbs 
et al., 1976), which is an endogenous anorectic 
agent (Kissileff et al., 1981). As a precursor of 
catecholamine neurotransmitters (Wurtman et 
al., 1981), phenylalanine may facilitate intake via 
the hypothalamic adrenoreceptors implicated in 
the central appetite control mechanisms, stimu-
lating appetite (Leibowitz, 1980). The ASP me-
tabolite aspartate is taken over from circulation 
by the arcuate (ARC) nucleus in the brain. The 
ARC nucleus is the main place for the synthesis 
of neuropeptide Y (NPY), which stimulates car-
bohydrate intake (Beck et al., 2001). Increased 
concentrations of glutamate, or its excitatory 
amino acid agonists, kainic acid, AMPA and 
NMDA, rapidly elicit an intense food intake re-
sponse in rats (Stanley et al., 1993). Aspartate 
is a N-Methyl-D-aspartate (NMDA) receptors 
agonist (Chen et al., 2005) and its increased con-
centration can influence food intake. 
Beck et al. (2001) reported that chronic ASP 
use significantly decreases the concentrations of 
leptin in plasma. Leptin acts on the brain by in-
hibiting food intake, but lower concentrations of 
leptin could stimulate appetite (Caro et al., 1996). 
Increased fluid intake can be associated with the 
intensive sweet taste of ASP and its hedonic im-
pact. ASP is about 200 times sweeter than su-
crose (Humphries et al., 2008). feijo et al. (2013) 
reported increased body weight and fluid intake 
in a group treated with ASP. There are opposing 
opinions about the effect of ASP on body weight 
changes. Some studies reported increased body 
weight caused by ASP (feijo et al. 2013, Choud-
hary and Devi 2014), while others showed that 
ASP is efficient in body weight loss (Blackburn et 
al. 1997; Blackburn, 1999). We observed signifi-
cantly increased appetite and lower weight gain 
in ASP-treated rats. The observed discrepancy 
suggests that ASP can affect energy (lipids and 
carbohydrates) metabolism, increasing energy 
expenditure. Other results reported in this study 
such as increased fluid intake, biochemical pa-
rameters in serum and oxidative stress also indi-
cate that chronic ASP treatment can possibly lead 
to the development of diabetes type 2 in rats. The 
classic symptoms of diabetes are polyuria (fre-
quent urination), polydipsia (increased thirst), 
polyphagia (increased hunger), and weight loss 
(Vijan, 2010). 
Treatment with ASP caused an increase in 
serum glucose, total cholesterol and LDL-cho-
lesterol, while the level of HDL-cholesterol was 
decreased as compared to the control. Choles-
terol is a major component of cell membranes. 
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It is essential for tissue growth and the produc-
tion of steroid hormones. The liver is the major 
organ responsible for the regulation of total-body 
cholesterol metabolism (evans et al., 1999). Simi-
lar results to those in our study were reported 
by Kim et al. (2011). Chronic exposure to ASP 
induced changes in biochemical parameters and 
lipid metabolism, and could be involved in the 
development of hyperglycemia and hypercho-
lesterolemia. Other authors have shown that the 
long-term consumption of artificial sweeteners, 
such as ASP, might contribute to hypersensitiv-
ity reactions (Walton, 1988) and atherosclerosis 
development (Jang et al., 2011). Hypercholester-
olemic atherosclerosis was associated with in-
creases in ROS, which represents a critical initi-
ating event in the development of atherosclerosis 
and cardiovascular diseases. Oxidative stress and 
oxidative damage of tissue could be the initial 
markers of some chronic diseases, like diabetes. 
During diabetes, persistent hyperglycemia causes 
the increased production of free radicals in all 
tissues from glucose auto-oxidation and protein 
glycosylation (Chaitanya et al., 2010).
The results presented in this study suggest 
that the number of WBC decreased in ASP-
treated rats. The reduced WBC number is due 
to a redistribution of cells into damaged organs 
such as the liver, rather than loss of cells (Dhab-
har and Mcewen, 1997). Based on literature data, 
hyperglycemia, hypercholesterolemia and hyper-
triglyceridemia activate neutrophils, increasing 
their adhesion to the endothelium and promot-
ing oxidative bursts (Alipour et al., 2008). These 
alterations may be due to the production of high 
levels of free radicals. free radicals are extremely 
reactive and have the capacity to interact with 
cellular macromolecules, including lipid mem-
branes, proteins, carbohydrates and nucleic acids, 
thus interfering with vital cellular functions (Hal-
liwell and Gutteridge, 2007).
We observed a significant increase in ALT, 
AST and LDH activities in ASP-treated rats. The 
increased levels of serum enzymes indicate an 
enhanced permeability, damage or necrosis of 
hepatocytes. The disturbance in the transport 
function of the hepatocytes because of hepatic in-
jury causes the leakage of enzymes from cells due 
to increased lipid peroxidation. It is likely that 
ASP induces biochemical changes in the liver. 
These alterations in enzyme levels may depend 
on exposure time and dose. Similar results were 
reported by Abhilash et al. (2011), Abdel-Salam 
et al. (2012) and Choudhary and Devi (2014).
Literature data shows that oxidative stress 
contributes to endothelial dysfunction by modu-
lating NO bioavailability in the microcirculation 
(Pandey and Rizvi, 2010). Based on our results, 
ASP treatment increased the concentrations of 
NO and LPO in erythrocytes. The increased lev-
els of LPO and NO are taken as direct evidence 
of oxidative stress (Humphries et al., 2008). This 
alteration after ASP administration may be at-
tributed to its metabolite methanol. Methanol 
is primarily metabolized by oxidation to form-
aldehyde and then to formate. These processes 
are accompanied by the formation of superoxide 
anion and hydrogen peroxide (Parthasarathy et 
al., 2006; Humphries et al., 2008). Lipid peroxi-
dation in cellular membranes damages polyun-
saturated fatty acids tending to reduce membrane 
fluidity, which could lead to the release of metha-
nol (formed during aspartame metabolism) and 
formaldehyde (formed during methanol me-
tabolism). This is well supported by the report 
of Parthasarathy et al. (2006), who observed an 
increased LPO level after methanol administra-
tion in the lymphoid organs. Similarly, Mourad 
(2011) recorded a significant increase in LPO 
level in the liver and kidney of rats after chronic 
ASP treatment.
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Table 3. effect of aspartame (ASP) on biochemical parameters 
in the serum.
Parameters Experimental groupsControl ASP
TP (g/L) 64.2 ± 1.81 68.6 ± 1.41
Alb (g/L) 12.4 ± 0.7 13.6 ± 0.6
Glucose (mg/dL) 96.5 ± 14.2 138.7 ± 12.4*
TC (mmol/L) 1.24 ± 0.06 1.86 ± 0.07*
HDLC (mmol/L) 0.76 ± 0.02 0.58 ± 0.03*
LDLC (mmol/L) 0.08 ± 0.01 0.23 ± 0.03*
ALT (IU/L) 52.4 ± 2.81 74.8 ± 5.16*
AST (IU/L) 141.6 ± 4.38 186.7 ± 6.24*
LDH (IU/L) 465.8 ± 23.6 798.3 ± 54.8*
TP: total protein; Alb: albumin; TC: total cholesterol; HDLC: high 
density lipoprotein cholesterol; LDLC: low density lipoprotein 
cholesterol; ALT: alanine aminotransferase; AST: aspartate ami-
notransferase; LDH: lactate dehidrogenase. Values are expressed 
as means ± SeM, (n = 5 animals). *p< 0.05 when compared with 
the control group.
Table 4. effect of aspartame (ASP) on blood NO, LPO, GSH, 
GSSG and GSH RI.
Parameters Experimental groupsControl Aspartame
NO (μmol/L) 29.34 ± 1.97 53.48 ± 2.49*
LPO (μmol/L) 3.28 ± 0.20 4.59 ± 0.23*
GSH (mmol/L) 5.58 ± 0.54 3.17 ± 0.18*
GSSG (μmol/L) 1.17 ± 0.10 2.24 ± 0.12*
GSH RI (AU) 3.91 ± 0.16 2.12 ± 0.24*
NO: nitric oxide; LPO: lipid peroxidation; GSH: reduced gluta-
thione; GSSG: oxidized glutathione; GSH RI: glutathione redox 
index (AU: Аrbitrary Unit). Values are expressed as means ± 
SeM, (n = 5 animals). *p<0.05 when compared with the control 
group.
Reduced glutathione is a primary defense 
against oxidative stress. The antioxidative role 
of GSH is based on its ability to scavenge free 
radicals, to reduce peroxides and to participate as 
a co-substrate in the activity of GSH-dependent 
enzymes. The thiol/disulfide (GSH/GSSG) ratio 
has an important effect on the redox status of the 
protein thiols with modulation of protein confor-
mation and enzyme activity. Moreover, oxygen-
derived free radicals may overwhelm the radical 
scavenging potential of cells, leading to lipid per-
oxidation and the destruction of cell membranes, 
which in turn may result in cellular depletion of 
GSH, with subsequent increases of GSSG. An 
increased GSSG/GSH ratio is considered indica-
tive of oxidative stress (Griffith, 1999; Shelly, 
2009). The decrease in GSH activity observed in 
the present study could be caused by methanol, 
because methanol metabolism depends upon 
GSH (Parthasarathy et al., 2006). The depletion 
of GSH, an increase in GSSG and the lowering of 
the GSH/GSSG ratio increase cell vulnerability 
to oxidative stress (Shelly, 2009). These changes 
seem to be due to the generation of free radicals 
by the methanol metabolite of ASP. GSH protects 
the cellular system against the toxic effects of 
lipid peroxidation (Griffith, 1999). Usually, GSH 
non-enzymatically reacts with superoxide, nitric 
oxide, hydroxyl radical and peroxynitrite radicals 
(Atasayar et al., 2009).
Our results provide evidence that ASP intake 
induces oxidative stress in rat erythrocytes by al-
tering the glutathione redox status. Together with 
the changes in biochemical and lipid parameters 
and indicators of liver damage, our findings sug-
gest that chronic use of ASP can lead to the de-
velopment hyperglycemia, hypercholesterolemia 
and associated diseases. In spite of the controver-
sial effects of ASP, it is used worldwide by diabet-
ics and people on different diets.
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